Current Size: 100%
- Data & statistics
- Performance indicators
- 5: Microscopically verified
5: Microscopically verified
Percentage (%) of microscopically verified cases (persons)
| UKIACR average (population) | UKIACR average (country) | England | Scotland | Wales | Northern Ireland | Republic of Ireland | |
|---|---|---|---|---|---|---|---|
| All invasive xnmsc | 85.4% | 85.8% | 85.4% | 84.2% | 80.4% | 86.7% | 92.1% |
| All xnmsc 0-24 | 92.7% | 89.3% | 94.2% | 97.7% | 86.8% | 94.9% | 72.7% |
| All xnmsc 25-59 | 96.2% | 96.0% | 96.2% | 96.5% | 92.0% | 97.4% | 98.1% |
| All xnmsc 60-79 | 89.2% | 89.1% | 89.3% | 87.7% | 83.8% | 90.3% | 94.7% |
| All xnmsc 80+ | 64.0% | 64.4% | 64.1% | 60.6% | 61.0% | 62.5% | 73.7% |
| All registrations | 90.0% | 88.9% | 90.2% | 89.7% | 78.6% | 90.5% | 95.3% |
| Haematology | 86.7% | 87.6% | 86.2% | 95.6% | 74.9% | 88.9% | 92.4% |
| Head and Neck | 97.2% | 97.0% | 97.3% | 97.0% | 96.1% | 98.3% | 96.1% |
| Lower GI | 89.3% | 90.0% | 89.1% | 88.8% | 84.4% | 93.0% | 94.9% |
| Upper GI | 92.7% | 91.4% | 93.1% | 92.5% | 86.1% | 90.8% | 94.4% |
| HPB | 52.1% | 54.6% | 51.9% | 44.4% | 50.2% | 58.7% | 67.6% |
| Trachea, Bronchus & Lung | 71.0% | 72.6% | 70.8% | 66.3% | 69.5% | 71.0% | 85.5% |
| Melanoma | 99.5% | 99.4% | 99.5% | 100.0% | 97.4% | 100.0% | 99.8% |
| Breast | 98.5% | 98.4% | 98.5% | 98.5% | 96.6% | 99.4% | 99.2% |
| Cervix | 98.1% | 97.2% | 98.4% | 97.6% | 96.7% | 96.3% | 97.0% |
| Other Female Genitals | 94.0% | 92.9% | 94.4% | 92.5% | 89.3% | 95.5% | 92.8% |
| Prostate | 87.1% | 88.6% | 86.4% | 89.0% | 84.5% | 86.4% | 96.6% |
| Kidney | 74.6% | 76.3% | 74.0% | 78.7% | 62.9% | 80.8% | 84.9% |
| Bladder | 90.1% | 89.5% | 90.4% | 88.1% | 85.4% | 89.7% | 93.7% |
| Brain and CNS | 70.8% | 70.1% | 70.8% | 70.6% | 61.5% | 69.3% | 78.4% |
| Thyroid & other endocrine glands | 96.1% | 93.8% | 96.7% | 96.0% | 88.8% | 95.4% | 92.2% |
| CUP | 48.4% | 46.7% | 48.9% | 46.7% | 30.0% | 41.7% | 66.0% |
| Other invasive cancer | 86.4% | 83.6% | 87.7% | 78.7% | 74.6% | 85.0% | 92.0% |
| Breast in situ | 99.9% | 99.5% | 100.0% | 100.0% | 97.9% | 100.0% | 99.8% |
| Cervix in situ | 99.9% | 99.7% | 100.0% | 100.0% | 98.3% | 100.0% | 100.0% |
| Other tumours | 87.4% | 83.0% | 88.7% | 92.9% | 51.2% | 85.7% | 96.5% |
Percentage (%) of non-specificity of morphology codes for cases which are microscopically verified
| UKIACR average (population) | UKIACR average (country) | England | Scotland | Wales | Northern Ireland | Republic of Ireland | |
|---|---|---|---|---|---|---|---|
| All invasive xnmsc | 2.0% | 3.7% | 1.5% | 1.5% | 11.0% | 1.5% | 2.8% |
| All xnmsc 0-24 | 2.6% | 8.4% | 1.0% | 0.7% | 37.6% | 0.9% | 1.9% |
| All xnmsc 25-59 | 1.4% | 2.8% | 0.9% | 0.8% | 9.3% | 0.7% | 2.4% |
| All xnmsc 60-79 | 1.9% | 3.4% | 1.4% | 1.5% | 9.9% | 1.6% | 2.8% |
| All xnmsc 80+ | 3.5% | 5.5% | 2.9% | 2.6% | 15.5% | 2.6% | 4.1% |
| All registrations | 1.5% | 3.1% | 1.1% | 1.1% | 8.7% | 2.7% | 1.7% |
| Haematology | 5.3% | 21.3% | 0.8% | 0.6% | 97.3% | 1.2% | 6.4% |
| Head and Neck | 1.9% | 1.9% | 1.9% | 1.7% | 1.2% | 2.0% | 3.0% |
| Lower GI | 1.0% | 1.2% | 0.9% | 0.4% | 3.0% | 0.5% | 1.2% |
| Upper GI | 1.9% | 2.2% | 1.8% | 1.6% | 3.4% | 1.6% | 2.4% |
| HPB | 6.4% | 7.8% | 5.9% | 6.7% | 15.2% | 5.2% | 6.3% |
| Trachea, Bronchus & Lung | 3.2% | 3.6% | 3.0% | 2.7% | 5.1% | 1.4% | 5.8% |
| Melanoma | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Breast | 1.0% | 1.3% | 0.9% | 1.5% | 1.2% | 2.0% | 1.2% |
| Cervix | 1.1% | 1.2% | 1.1% | 0.3% | 1.4% | 1.3% | 2.2% |
| Other Female Genitals | 1.3% | 1.7% | 1.2% | 0.7% | 3.0% | 0.8% | 2.9% |
| Prostate | 0.5% | 0.7% | 0.4% | 0.3% | 2.0% | 0.3% | 0.5% |
| Kidney | 1.3% | 1.8% | 1.2% | 1.7% | 2.0% | 1.5% | 2.7% |
| Bladder | 0.9% | 1.5% | 0.8% | 0.1% | 1.9% | 2.1% | 2.6% |
| Brain and CNS | 0.5% | 0.7% | 0.5% | 0.7% | 1.8% | 0.0% | 0.7% |
| Thyroid & other endocrine glands | 2.4% | 2.2% | 2.4% | 1.0% | 1.8% | 1.2% | 4.6% |
| CUP | 19.4% | 19.9% | 19.5% | 15.8% | 30.6% | 14.7% | 19.1% |
| Other invasive cancer | 1.5% | 2.7% | 1.1% | 0.8% | 3.0% | 3.5% | 5.0% |
| Breast in situ | 0.2% | 0.2% | 0.2% | 0.2% | 0.0% | 0.4% | 0.2% |
| Cervix in situ | 0.1% | 0.2% | 0.1% | 0.0% | 0.5% | 0.0% | 0.2% |
| Other tumours | 3.5% | 6.6% | 2.9% | 2.1% | 16.1% | 12.0% | 0.0% |
Printer-friendly versionBuilding 6800
Cork Airport Business Park
Kinsale Road, Cork T12 CDF7
Email Contact us here
Tel: +353 (0) 21 4318014
Fax: +353 (0) 21 4318016
© National Cancer Registry 2024
